Vaccine strategies: Optimising outcomes

Vaccine

Volumn 34, Issue 52, 2016, Pages 6691-6699

  Hardt, Karin ^a   Bonanni, Paolo ^b   King, Susan ^a   Santos, Jose Ignacio ^c   El Hodhod, Mostafa ^d   Zimet, Gregory D ^e   Preiss, Scott ^a  

^a GSK   (Belgium)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d AIN SHAMS UNIVERSITY   (Egypt)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coverage; Implementation; National immunisation programme; Planning; Strategy; Vaccination

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; WART VIRUS VACCINE; VACCINE;

ARTICLE; CONCEPTUAL FRAMEWORK; FUNDING; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HIGH INCOME COUNTRY; HUMAN; INTERPERSONAL COMMUNICATION; PRIORITY JOURNAL; VACCINATION; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DISEASE TRANSMISSION; GLOBAL HEALTH; HEALTH CARE POLICY; ORGANIZATION AND MANAGEMENT; PREVENTION AND CONTROL; PREVENTIVE HEALTH SERVICE; UTILIZATION;

DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DISEASE TRANSMISSION, INFECTIOUS; GLOBAL HEALTH; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; VACCINATION; VACCINES;

EID: 85001022272     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.10.078     Document Type: Article

References (86)

1. [1] Schlipköter, U., Flahault, A., Communicable diseases: achievements and challenges for public health. Public Health Rev 32 (2010), 90–119.
2. [2] Hajj Hussein, I., Chams, N., Chams, S., El Sayegh, S., Badran, R., Raad, M., et al. Vaccines through centuries: major cornerstones of global health. Front Public Health, 3, 2015, 269.
3. [3] Andre, F.E., Booy, R., Bock, H.L., Clemens, J., Datta, S.K., John, T.J., et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ 86 (2008), 140–146.
4. [4] World Health Organization. Immunization coverage. < http://www.who.int/mediacentre/factsheets/fs378/en/> [accessed 21.04.16].
5. [5] Subaiya, S., Dumolard, L., Lydon, P., Gacic-Dobo, M., Eggers, R., Conklin, L., Global routine vaccination coverage, 2014. MMWR Morb Mortal Wkly Rep 64 (2015), 1252–1255.
6. [6] Paterson, P., Meurice, F., Stanberry, L.R., Glismann, S., Rosenthal, S.L., Larson, H., Vaccine hesitancy and healthcare providers. Vaccine 34 (2016), 6700–6706, 10.1016/j.vaccine.2016.10.042.
7. [7] Kim, T.H., Johnstone, J., Loeb, M., Vaccine herd effect. Scand J Infect Dis 43 (2011), 683–689.
8. [8] Doherty, M., Buchy, P., Standaert, B., Giaquinto, C., Prado-Cohrs, D., Vaccine impact: benefits for human health. Vaccine 34 (2016), 6707–6714, 10.1016/j.vaccine.2016.10.025.
9. [9] Scarbrough Lefebvre, C.D., Terlinden, A., Standaert, B., Dissecting the indirect effects caused by vaccines into the basic elements. Hum Vaccin Immunother 11 (2015), 2142–2157.
10. [10] World Health Organization. Vaccine introduction guidelines. Adding a vaccine to a national immunization programme: decision and implementation. WHO/IVB/05.18. Geneva, Switzerland; 2005.
11. [11] Doherty, M., Schmidt-Ott, R., Santos, J.I., Stanberry, L.R., Hofstetter, A.M., Rosenthal, S.L., et al. Vaccination of special populations: protecting the vulnerable. Vaccine 34 (2016), 6681–6690, 10.1016/j.vaccine.2016.11.015.
12. [12] Bonanni, P., Sacco, C., Donato, R., Capei, R., Lifelong vaccination as a key disease-prevention strategy. Clin Microbiol Infect 20:Suppl 5 (2014), 32–36.
13. [13] Bonanni, P., Universal hepatitis B immunization: infant, and infant plus adolescent immunization. Vaccine 16:Suppl (1998), S17–S22.
14. [14] Donaghy, M., Cameron, J.C., Friederichs, V., Increasing incidence of mumps in Scotland: options for reducing transmission. J Clin Virol 35 (2006), 121–129.
15. [15] Heymann, D.L., Aylward, R.B., Mass vaccination: when and why. Curr Top Microbiol Immunol 304 (2006), 1–16.
16. [16] Minor, P., The polio endgame. Hum Vaccin Immunother 10 (2014), 2106–2108.
17. [17] Keeling, M., Tildesley, M., House, T., Danon, L., The mathematics of vaccination. Math Today 40 (2013), 40–43.
18. [18] Indian Academy of Pediatrics. IAP guidebook on immunization: licensing procedure and inclusion of a vaccine in the National Immunization Program (NIP) of a country. < http://www.iapcoi.com/hp/pdf/IAP%20GUIDE%20BOOK%20ON%20IMMUNIZATION%20LICENSING%20PROCEDURE%20AND%20INCLUSION%20OF%20A%20VACCINE%20IN%20THE%20NATIONAL%20IMMUNIZATION%20PROGRAM%20(NIP)%20OF%20A%20COUNTRY.pdf> [accessed 21.04.16].
19. [19] Hyde, T.B., Dentz, H., Wang, S.A., Burchett, H.E., Mounier-Jack, S., Mantel, C.F., The impact of new vaccine introduction on immunization and health systems: a review of the published literature. Vaccine 30 (2012), 6347–6358.
20. [20] International Agency for Research on Cancer. Cervical cancer. Estimated incidence, mortality and prevalence worldwide in 2012. < http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx> [accessed 21.04.16].
21. [21] Sankaranarayanan, R., Anorlu, R., Sangwa-Lugoma, G., Denny, L.A., Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa. Vaccine 31:Suppl 5 (2013), F47–F52.
22. [22] Muñoz, N., Franco, E.L., Herrero, R., Andrus, J.K., de Quadros, C., Goldie, S.J., et al. Recommendations for cervical cancer prevention in Latin America and the Caribbean. Vaccine 26:Suppl 11 (2008), L96–L107.
23. [23] Bosch, F.X., Broker, T.R., Forman, D., Moscicki, A.B., Gillison, M.L., Doorbar, J., et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine 31:Suppl 8 (2013), I1–31.
24. [24] LaMontagne, D.S., Barge, S., Le, N.T., Mugisha, E., Penny, M.E., Gandhi, S., et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ, 89, 2011 821-30B.
25. [25] Wigle, J., Fontenot, H.B., Zimet, G.D., Global delivery of human papillomavirus vaccines. Pediatr Clin North Am 63 (2016), 81–95.
26. [26] Kane, M.A., Serrano, B., de Sanjose, S., Wittet, S., Implementation of human papillomavirus immunization in the developing world. Vaccine 30:Suppl 5 (2012), F192–F200.
27. [27] GAVI Alliance. Immunization financing toolkit. A resource for policy-makers and program managers. < http://www.gavi.org/library/publications/other-publishers/> [accessed 21.04.16].
28. [28] Ngabo, F., Levin, A., Wang, S.A., Gatera, M., Rugambwa, C., Kayonga, C., et al. A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda. Vaccine 33 (2015), 7357–7363.
29. [29] Levine, M.M., Robins-Browne, R., Vaccines, global health and social equity. Immunol Cell Biol 87 (2009), 274–278.
30. [30] DeRoeck, D., Bawazir, S.A., Carrasco, P., Kaddar, M., Brooks, A., Fitzsimmons, J., et al. Regional group purchasing of vaccines: review of the Pan American Health Organization EPI revolving fund and the Gulf Cooperation Council group purchasing program. Int J Health Plann Manage 21 (2006), 23–43.
31. [31] Sáfadi, M.A., O'Ryan, M., Valenzuela Bravo, M.T., Brandileone, M.C., Gorla, M.C., de Lemos, A.P., et al. The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations. Vaccine 33 (2015), 6529–6536.
32. [32] Bhutan Health Trust Fund. Bhutan Health Trust Fund. Towards sustaining primary health care services in Bhutan. < http://www.bhtf.bt/> [accessed 21.04.16].
33. [33] Hardt, K., Schmidt-Ott, R., Glismann, S., Adegbola, R.A., Meurice, F.P., Sustaining vaccine confidence in the 21st century. Vaccines (Basel) 1 (2013), 204–224.
34. [34] Koch-Institut, Robert, Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2004. Epidemiologisches Bull 30 (2004), 235–250.
35. [35] Siedler, A., Arndt, U., Impact of the routine varicella vaccination programme on varicella epidemiology in Germany. Euro Surveill, 15, 2010.
36. [36] Spackova, M., Wiese-Posselt, M., Dehnert, M., Matysiak-Klose, D., Heininger, U., Siedler, A., Comparative varicella vaccine effectiveness during outbreaks in day-care centres. Vaccine 28 (2010), 686–691.
37. [37] Seward, J.F., Marin, M., Vazquez, M., Varicella vaccine effectiveness in the US vaccination program: a review. J Infect Dis 197:Suppl 2 (2008), S82–S89.
38. [38] Marin, M., Güris, D., Chaves, S.S., Schmid, S., Seward, J.F., Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56 (2007), 1–40.
39. [39] Koch-Institut, Robert., Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2009. Epidemiologisches Bull 30 (2009), 279–298.
40. [40] Streng, A., Grote, V., Carr, D., Hagemann, C., Liese, J.G., Varicella routine vaccination and the effects on varicella epidemiology - results from the Bavarian Varicella Surveillance Project (BaVariPro), 2006–2011. BMC Infect Dis, 13, 2013, 303.
41. [41] Jauregui, B., Garcia, A.G., Bess Janusz, C., Blau, J., Munier, A., Atherly, D., et al. Evidence-based decision-making for vaccine introductions: Overview of the ProVac International Working Group's experience. Vaccine 33:Suppl 1 (2015), A28–A33.
42. [42] Andrus, J.K., Toscano, C.M., Lewis, M., Oliveira, L., Ropero, A.M., Davila, M., et al. A model for enhancing evidence-based capacity to make informed policy decisions on the introduction of new vaccines in the Americas: PAHO's ProVac initiative. Public Health Rep 122 (2007), 811–816.
43. [43] Senouci, K., Blau, J., Nyambat, B., Coumba Faye, P., Gautier, L., Da Silva, A., et al. The Supporting Independent Immunization and Vaccine Advisory Committees (SIVAC) initiative: a country-driven, multi-partner program to support evidence-based decision making. Vaccine 28:Suppl 1 (2010), A26–A30.
44. [44] Agence de Médecine Préventive. Health Policy and Institutional Development. < http://amp-vaccinology.org/HPID> [accessed 21.04.16].
45. [45] Health Policy and Institutional Development (HPID) unit at the AMP. NITAG Resource Center. < http://www.nitag-resource.org/who-we-are> [accessed 26.08.16].
46. [46] Adjagba, A., Senouci, K., Biellik, R., Batmunkh, N., Faye, P.C., Durupt, A., et al. Supporting countries in establishing and strengthening NITAGs: lessons learned from 5 years of the SIVAC initiative. Vaccine 33 (2015), 588–595.
47. [47] Nolan, T.M., The Australian model of immunization advice and vaccine funding. Vaccine 28:Suppl 1 (2010), A76–A83.
48. [48] European Centre for Disease Prevention and Control (ECDC). Current practices in immunisation policymaking in European countries. < http://ecdc.europa.eu/en/publications/Publications/Current-practices-on-immunisation-policymaking-processes-Mar-2015.pdf> [accessed 26.08.16].
49. [49] World Health Organization, Pneumococcal vaccines. WHO position paper - 2012. Wkly Epidemiol Rec 87 (2012), 129–144.
50. [50] Costantino, C., Vitale, F., Influenza vaccination in high-risk groups: a revision of existing guidelines and rationale for an evidence-based preventive strategy. J Prev Med Hyg 57 (2016), E13–E18.
51. [51] World Health Organization. South African Vaccination and Immunisation Centre (SAVIC). < http://www.who.int/vaccine_safety/initiative/communication/network/SAVIC/en/> [accessed 26.08.16].
52. [52] University of Antwerp. Network for Education and Support in Immunisation. < http://www.nesi.be/> [accessed 26.08.16].
53. [53] University of Cape Town. Vaccines for Africa Initiative. < http://www.vacfa.uct.ac.za/> [accessed 26.08.16].
54. [54] International Vaccine Institute. About IVI. < http://www.ivi.org/web/www/home> [accessed 26.08.16].
55. [55] ECAVI. East Africa Centre for Vaccines and Immunization (ECAVI). < http://www.e-cavi.com/> [accessed 26.08.16].
56. [56] Network for Education and Support in Immunisation. HPV workshop: ’Implementing HPV vaccination in Africa: opportunities for strengthening adolescent health’. < http://www.nesi.be/area-of-work/training/3/2016#303> [accessed 26.08.16].
57. [57] Carrasco, P., Franco-Paredes, C., Andrus, J., Waller, K., Maassen, A., Symenouh, E., et al. Inaugural conference of the International Association of Immunization Managers (IAIM), Istanbul Turkey, 3–4 March 2015. Vaccine 33 (2015), 4047–4050.
58. [58] Thacker, N., Vashishtha, V.M., Awunyo-Akaba, J., Mistry, R.F., Civil society organizations, the implementing partners of the Global Vaccine Action Plan. Vaccine 31:Suppl 2 (2013), B97–B102.
59. [59] Wallace, A.S., Mantel, C., Mayers, G., Mansoor, O., Gindler, J.S., Hyde, T.B., Experiences with provider and parental attitudes and practices regarding the administration of multiple injections during infant vaccination visits: lessons for vaccine introduction. Vaccine 32 (2014), 5301–5310.
60. [60] Domingues, C.M., de Fatima, Pereira S., Cunha Marreiros, A.C., Menezes, N., Flannery, B., Introduction of sequential inactivated polio vaccine-oral polio vaccine schedule for routine infant immunization in Brazil's National Immunization Program. J Infect Dis 210:Suppl 1 (2014), S143–S151.
61. [61] Castillo-Solórzano, C., Marsigli, C., Bravo-Alcántara, P., Flannery, B., Ruiz Matus, C., Tambini, G., et al. Elimination of rubella and congenital rubella syndrome in the Americas. J Infect Dis 204:Suppl 2 (2011), S571–S578.
62. [62] Mokdad, A.H., Gagnier, M.C., Colson, K.E., Dansereau, E., Zuniga-Brenes, P., Rios-Zertuche, D., et al. Missed opportunities for measles, mumps, and rubella (MMR) immunization in Mesoamerica: potential impact on coverage and days at risk. PLoS ONE, 10, 2015, e0139680.
63. [63] Rani, M., Yang, B., Nesbit, R., Hepatitis B control by 2012 in the WHO Western Pacific Region: rationale and implications. Bull World Health Organ 87 (2009), 707–713.
64. [64] Amirthalingam, G., Andrews, N., Campbell, H., Ribeiro, S., Kara, E., Donegan, K., et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 384 (2014), 1521–1528.
65. [65] Dylag, A.M., Shah, S.I., Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit. Pediatrics 122 (2008), e550–e555.
66. [66] Sugaya, N., A review of the indirect protection of younger children and the elderly through a mass influenza vaccination program in Japan. Expert Rev Vaccines 13 (2014), 1563–1570.
67. [67] Castilla, J., Martinez-Baz, I., Godoy, P., Toledo, D., Astray, J., Garcia, S., et al. Trends in influenza vaccine coverage among primary healthcare workers in Spain, 2008–2011. Prev Med 57 (2013), 206–211.
68. [68] Domingues, C.M., de Oliveira, W.K., Uptake of pandemic influenza (H1N1)-2009 vaccines in Brazil, 2010. Vaccine 30 (2012), 4744–4751.
69. [69] Verguet, S., Jassat, W., Hedberg, C., Tollman, S., Jamison, D.T., Hofman, K.J., Measles control in Sub-Saharan Africa: South Africa as a case study. Vaccine 30 (2012), 1594–1600.
70. [70] Public Health England. Human papillomavirus (HPV) vaccine coverage in England, 2008/09 to 2013/14. A review of the full six years of the three-dose schedule. < https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/412264/HPV_Vaccine_Coverage_in_England_200809_to_201314.pdf> [accessed 21.04.16].
71. [71] Brotherton, J.M., Murray, S.L., Hall, M.A., Andrewartha, L.K., Banks, C.A., Meijer, D., et al. Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach. Med J Aust 199 (2013), 614–617.
72. [72] Reagan-Steiner, S., Yankey, D., Jeyarajah, J., Elam-Evans, L.D., Singleton, J.A., Curtis, C.R., et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years–United States, 2014. MMWR Morb Mortal Wkly Rep 64 (2015), 784–792.
73. [73] Mongua-Rodriguez, N., Diaz-Ortega, J.L., Garcia-Garcia, L., Pina-Pozas, M., Ferreira-Guerrero, E., Delgado-Sanchez, G., et al. A systematic review of rubella vaccination strategies implemented in the Americas: impact on the incidence and seroprevalence rates of rubella and congenital rubella syndrome. Vaccine 31 (2013), 2145–2151.
74. [74] Franco-Paredes, C., Hernandez-Ramos, I., Santos-Preciado, J.I., Immunization and equity in the Regional Initiative of the Mesoamerican Health Initiative. Salud Publica Mex 53:Suppl 3 (2011), S323–S332.
75. [75] Goldstein, S.T., Zhou, F., Hadler, S.C., Bell, B.P., Mast, E.E., Margolis, H.S., A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 34 (2005), 1329–1339.
76. [76] Locarnini, S., Hatzakis, A., Chen, D.S., Lok, A., Strategies to control hepatitis B: public policy, epidemiology, vaccine and drugs. J Hepatol 62 (2015), S76–S86.
77. [77] Hennessey, K., Schluter, W.W., Wang, X., Boualam, L., Jee, Y., Mendoza-Aldana, J., et al. Are we there yet? Assessing achievement of vaccine-preventable disease goals in WHO's Western Pacific Region. Vaccine 32 (2014), 4259–4266.
78. [78] Charu, V., Viboud, C., Simonsen, L., Sturm-Ramirez, K., Shinjoh, M., Chowell, G., et al. Influenza-related mortality trends in Japanese and American seniors: evidence for the indirect mortality benefits of vaccinating schoolchildren. PLoS ONE, 6, 2011, e26282.
79. [79] Sugaya, N., Takeuchi, Y., Mass vaccination of schoolchildren against influenza and its impact on the influenza-associated mortality rate among children in Japan. Clin Infect Dis 41 (2005), 939–947.
80. [80] Amirthalingam, G., Strategies to control pertussis in infants. Arch Dis Child 98 (2013), 552–555.
81. [81] Heininger, U., Weibel, D., Richard, J.L., Prospective nationwide surveillance of hospitalizations due to pertussis in children, 2006–2010. Pediatr Infect Dis J 33 (2014), 147–151.
82. [82] Forsyth, K., Plotkin, S., Tan, T., Wirsing von Konig, C.H., Strategies to decrease pertussis transmission to infants. Pediatrics 135 (2015), e1475–e1482.
83. [83] van Hoek, A.J., Campbell, H., Amirthalingam, G., Andrews, N., Miller, E., Cost-effectiveness and programmatic benefits of maternal vaccination against pertussis in England. J Infect 73 (2016), 28–37.
84. [84] Middleman, A., School-located vaccination for adolescents: past, present, and future and implications for HPV vaccine delivery. Hum Vaccin Immunother 12 (2016), 1599–1605.
85. [85] Berlier, M., Barry, R., Shadid, J., Sirica, C., Brunier, A., Hasan, H., et al. Communication challenges during the development and introduction of a new meningococcal vaccine in Africa. Clin Infect Dis 61:Suppl 5 (2015), S451–S458.
86. [86] El Gammal, H.A., Maternal satisfaction about childhood immunization in primary health care center, Egypt. Pan Afr Med J, 18, 2014, 157.